for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Andrew Ko



The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.

Official Title

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer


This is a randomized, double-blind, placebo-controlled Phase 2 study of MM-141 plus nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status. Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine and patients. Patients with low free IGF-1 or patients who have high free IGF-1 but are not otherwise eligible will be followed in an observational group.


Pancreatic Cancer Front-line Pancreatic Cancer Metastatic Pancreatic Cancer Gemcitabine Nab-paclitaxel Abraxane Free IGF-1 Heregulin Pancreatic Neoplasms Paclitaxel Albumin-Bound Paclitaxel MM-141


You can join if…

Open to people ages 18 years and up

  • Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not eligible.
  • Patient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.
  • Blood sample sent for free IGF-1 testing
  • ECOG performance status (PS) of 0 or 1

You CAN'T join if...

  • Patients who only present with localized disease
  • Patients with CNS malignancies (primary or metastatic)
  • Clinically significant cardiac disease


  • UCSF Cancer Center
    San Francisco California 94115 United States
  • Central Coast Med Onc Corp
    Santa Maria California 93454 United States
  • Sansum Clinic
    Santa Barbara California 93105 United States
  • UCLA School of Medicine
    Los Angeles California 90095 United States
  • Cancer Care Assoc Med Grp
    Redondo Beach California 90277 United States
  • St. Jude Heritage Healthcare
    Fullerton California 92835 United States
  • Pacific Cancer Medical Center, Inc.
    Anaheim California 92801 United States
  • Compr Cancer Centers of Nevada
    Henderson Nevada United States


in progress, not accepting new patients
Start Date
Completion Date
Merrimack Pharmaceuticals
Phase 2
Lead Scientist
Andrew Ko
Study Type
Last Updated
November 30, 2017